These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

378 related items for PubMed ID: 16541480

  • 21. Conventional lipid profile and lipoprotein(a) concentrations in treated patients with rheumatoid arthritis.
    García-Gómez C, Nolla JM, Valverde J, Gómez-Gerique JA, Castro MJ, Pintó X.
    J Rheumatol; 2009 Jul; 36(7):1365-70. PubMed ID: 19369465
    [Abstract] [Full Text] [Related]

  • 22. Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease.
    Koutroubakis IE, Oustamanolakis P, Malliaraki N, Karmiris K, Chalkiadakis I, Ganotakis E, Karkavitsas N, Kouroumalis EA.
    Eur J Gastroenterol Hepatol; 2009 Mar; 21(3):283-8. PubMed ID: 19279474
    [Abstract] [Full Text] [Related]

  • 23. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.
    Chopin F, Garnero P, le Henanff A, Debiais F, Daragon A, Roux C, Sany J, Wendling D, Zarnitsky C, Ravaud P, Thomas T.
    Ann Rheum Dis; 2008 Mar; 67(3):353-7. PubMed ID: 17644538
    [Abstract] [Full Text] [Related]

  • 24. Treatment of refractory inflammatory monoarthritis in ankylosing spondylitis by intraarticular injection of infliximab.
    Schatteman L, Gyselbrecht L, De Clercq L, Mielants H.
    J Rheumatol; 2006 Jan; 33(1):82-5. PubMed ID: 16292792
    [Abstract] [Full Text] [Related]

  • 25. Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients.
    Morris SJ, Wasko MC, Antohe JL, Sartorius JA, Kirchner HL, Dancea S, Bili A.
    Arthritis Care Res (Hoboken); 2011 Apr; 63(4):530-4. PubMed ID: 21452265
    [Abstract] [Full Text] [Related]

  • 26. Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function.
    Ernestam S, Hafström I, Werner S, Carlström K, Tengstrand B.
    J Rheumatol; 2007 Jul; 34(7):1451-8. PubMed ID: 17477470
    [Abstract] [Full Text] [Related]

  • 27. Intravascular tumor necrosis factor alpha blockade reverses endothelial dysfunction in rheumatoid arthritis.
    Cardillo C, Schinzari F, Mores N, Mettimano M, Melina D, Zoli A, Ferraccioli G.
    Clin Pharmacol Ther; 2006 Sep; 80(3):275-81. PubMed ID: 16952494
    [Abstract] [Full Text] [Related]

  • 28. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
    Sekiguchi N, Kawauchi S, Furuya T, Inaba N, Matsuda K, Ando S, Ogasawara M, Aburatani H, Kameda H, Amano K, Abe T, Ito S, Takeuchi T.
    Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
    [Abstract] [Full Text] [Related]

  • 29. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
    Yang CH, Huang F, Deng XH, Zhang JL, Zhang LY, Guo JH, Liang DF, Wang LS, Zhang YM.
    Zhonghua Yi Xue Za Zhi; 2006 Sep 19; 86(35):2451-4. PubMed ID: 17156669
    [Abstract] [Full Text] [Related]

  • 30. Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy.
    Comby E, Tanaff P, Mariotte D, Costentin-Pignol V, Marcelli C, Ballet JJ.
    J Rheumatol; 2006 Jan 19; 33(1):24-30. PubMed ID: 16395746
    [Abstract] [Full Text] [Related]

  • 31. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab.
    Sieper J, Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Braun J.
    Rheumatology (Oxford); 2005 Dec 19; 44(12):1525-30. PubMed ID: 16091396
    [Abstract] [Full Text] [Related]

  • 32. [Anti-lipoprotein autoantibodies with hypolipidemia in infectious rheumatism].
    Noseda G.
    Schweiz Med Wochenschr; 1975 Dec 19; 105(31 Suppl):1-58. PubMed ID: 168637
    [Abstract] [Full Text] [Related]

  • 33. Effects of a 6-month infliximab treatment on plasma levels of leptin and adiponectin in patients with rheumatoid arthritis.
    Derdemezis CS, Filippatos TD, Voulgari PV, Tselepis AD, Drosos AA, Kiortsis DN.
    Fundam Clin Pharmacol; 2009 Oct 19; 23(5):595-600. PubMed ID: 19563510
    [Abstract] [Full Text] [Related]

  • 34. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response.
    Braun J, Baraliakos X, Listing J, Fritz C, Alten R, Burmester G, Krause A, Schewe S, Schneider M, Sörensen H, Zeidler H, Sieper J.
    Ann Rheum Dis; 2008 Mar 19; 67(3):340-5. PubMed ID: 17967831
    [Abstract] [Full Text] [Related]

  • 35. Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis.
    Seriolo B, Paolino S, Sulli A, Fasciolo D, Cutolo M.
    Ann N Y Acad Sci; 2006 Jun 19; 1069():414-9. PubMed ID: 16855168
    [Abstract] [Full Text] [Related]

  • 36. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.
    Park MC, Chung SJ, Park YB, Lee SK.
    Scand J Rheumatol; 2008 Jun 19; 37(3):173-8. PubMed ID: 18465450
    [Abstract] [Full Text] [Related]

  • 37. Tumour necrosis factor-alpha (TNF-alpha) levels and influence of -308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis.
    Cuchacovich M, Ferreira L, Aliste M, Soto L, Cuenca J, Cruzat A, Gatica H, Schiattino I, Pérez C, Aguirre A, Salazar-Onfray F, Aguillón JC.
    Scand J Rheumatol; 2004 Jun 19; 33(4):228-32. PubMed ID: 15370717
    [Abstract] [Full Text] [Related]

  • 38. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study.
    van den Bemt BJ, den Broeder AA, Snijders GF, Hekster YA, van Riel PL, Benraad B, Wolbink GJ, van den Hoogen FH.
    Ann Rheum Dis; 2008 Dec 19; 67(12):1697-701. PubMed ID: 18245109
    [Abstract] [Full Text] [Related]

  • 39. Correlation of CX3CL1 and CX3CR1 levels with response to infliximab therapy in patients with rheumatoid arthritis.
    Odai T, Matsunawa M, Takahashi R, Wakabayashi K, Isozaki T, Yajima N, Miwa Y, Kasama T.
    J Rheumatol; 2009 Jun 19; 36(6):1158-65. PubMed ID: 19369458
    [Abstract] [Full Text] [Related]

  • 40. Tumor necrosis factor-α inhibitor use is not associated with lipid changes in rheumatoid arthritis.
    Bili A, Morris SJ, Sartorius JA, Kirchner HL, Antohe JL, Dancea S, Wasko MC.
    J Rheumatol; 2012 May 19; 39(5):946-8. PubMed ID: 22467937
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.